Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
We have now added a new section called the "Assay History List" to the "At A Gla...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...